News &

Press

venBio news

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering

Apr 22, 2021

Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs

Mar 9, 2021

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

Mar 1, 2021

Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

Feb 26, 2021

Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies

Jan 28, 2021

Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients

Jan 8, 2021

Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO

Jan 5, 2021

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2023 venBio. All Rights Reserved.